[New possibilities in antibacterial treatment of intra-abdominal infections caused by multiresistant microflora].

Autor:	Dibirov MD; Department of Surgery and Clinical Angiology at Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia., Khachatryan NN; Department of Surgery and Clinical Angiology at Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia., Isaev AI; Department of Surgery and Clinical Angiology at Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia., Karsotyan GS; Department of Surgery and Clinical Angiology at Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia., Alimova EE; Moscow city hospital named after S.I. Spasokukotskiy, Moscow, Russia., Kostyuk EA; Moscow city hospital named after S.I. Spasokukotskiy, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Khirurgiia [Khirurgiia (Mosk)] 2019 (12), pp. 74-83.
DOI:	10.17116/hirurgia201912174
Abstrakt:	Aim: To determine the place of new drugs with activity against multidrug resistant strains of microorganisms in the treatment of complicated intraabdominal infections. Material and Methods: The incidence and distribution of pathogens isolated from intra-abdominal specimens in patients with intra-abdominal infections are analyzed. Results: The current situation on the growth of resistant strains among pathogens causing intra-abdominal infections is rewied. New combined drugs for the treatment of multidrug resistant infections - ceftolozane/tazobactam and ceftazidim/avibactam plus metronidazole, has been suggested. Their potential role in empiric and targeted antibacterial treatment of complicated intraabdominal infections is defined. Conclusion: Taking into consideration local monitoring data and risk factors of multi resistant strains Ceftolozane/tazobactam in combination with metronidazole can be used in empiric regime of treatment. Due to the high activity on carbapenem resistant strains of Klebsiella pneumonia and the lack of alternatives, it is advisable to use Ceftazidim/avibactam for the targeted therapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu